Accessibility Menu

Obsidian Therapeutics(NASDAQ) OBX

Market Cap$31.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 YearN/A
1 YearN/A
1 MonthN/A
$30.00
+5.23%
+1.49Today
Pre market$26.99-$3.01 (-10.03%)
Obsidian Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 27.502026-08-07
Obsidian Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
Since inception-99.2%USD 3,419.292019-11-07

Obsidian Therapeutics Financials at a Glance

Market Cap

$31.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$149.04

EPS (TTM)

$396.88

P/E Ratio

0.07

Dividend

$0.00

Beta (Volatility)

56.91 (High)

Price

$30.00

Volume

8,856

Open

$27.54

Previous Close

$27.50

Daily Range

$26.80 - $28.45

52-Week Range

$23.00 - $49.97

Estimated Earnings Date

Aug 12, 2026

OBX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Obsidian Therapeutics

Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing engineered tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Utilizing proprietary cytoDRiVE® technology, the company aims to precisely regulate protein function through FDA-approved small-molecule drugs.

Products and Services
  • Engineered TIL cell therapies targeting solid tumors
  • Proprietary cytoDRiVE® technology for protein regulation
  • Innovative approaches to cancer treatment
Growth Outlook
  • Potential for significant market share in oncology therapeutics
  • Advancements in TIL therapies could lead to breakthrough treatments
  • Strong pipeline with ongoing clinical trials and research initiatives
Financial Highlights
  • Market capitalization of approximately $29.5 million
  • Stock price range between $15.57 and $49.97 over the past year
  • Recent trading volume of 7,413 shares indicates investor interest
Obsidian Therapeutics Inc. operates in the biotechnology sector, focusing on innovative cancer therapies. The company's unique approach to protein regulation positions it well within the competitive landscape of oncology. With a market capitalization of around $29.5 million, the stock has experienced a notable price range over the past year, reflecting both growth potential and market interest. The ongoing development of engineered TIL therapies and the proprietary cytoDRiVE® technology may provide significant advancements in cancer treatment, appealing to investors looking for opportunities in the healthcare sector.
AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

Website

www.galeratx.com

Headquarters

Cambridge, MA 02138, US

OBX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

14.29%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$31.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.16M

Volume

8.86K

Avg. Volume

12.01K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Obsidian Therapeutics Performance Analysis

Obsidian Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Obsidian Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -459.43-26.4%
20232023-12-31USD -265.24-42.3%
20242024-12-31USD -69.40-73.8%
20252025-12-31USD 302.63N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$31.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

3

N/A

Net Income

-$1.61

+1.0%

EBITDA

-$1.66

+0.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.50

-96.5%

Total Debt

$0.00

+0.0%

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

+0.0%

Short Term Debt

$0.00

N/A

Return on Assets

2156.02%

-18.2%

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$0.88

+0.4%

Operating Cash Flow

-$0.88

+0.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,757.64+0.01%
^DJIDJI
$54,036.93+0.00%
^IXICNASDAQ
$26,690.62+0.01%
BTCBitcoin
$64,991.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.11+0.06%

Questions About OBX

What is the current price of Obsidian Therapeutics?

Obsidian Therapeutics is trading at $27.50 per share.

What is the 52-week range for Obsidian Therapeutics?

Over the past 52 weeks, Obsidian Therapeutics has traded between $23.00 and $49.97.

How much debt does Obsidian Therapeutics have?

As of the most recent reporting period, Obsidian Therapeutics reported total debt of $0.00.

How much cash does Obsidian Therapeutics have on hand?

Obsidian Therapeutics reported $5.50M in cash and cash equivalents in its most recent financial results.

What is Obsidian Therapeutics’s dividend yield?

Obsidian Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services